allogene.com — August 2026 traffic, keywords & AI visibility

allogene.com draws an estimated 3,201 visits a month from search engines. Effectively all of it is organic — about 3,201 visits from unpaid results. Spread across 276 ranking keywords, that averages roughly 12 organic visits per keyword.

On our AI visibility scale allogene.com earns 59 of 100 points, a grade D. It takes full marks for LLMS.txt. The biggest gap is SEO health, at 0 of 20 points (0/100), worth 20 points if closed. It also loses points on Crawlability (0/10), Company profile (19/25) and Structured data (0/5).

The llms.txt on allogene.com runs to 75 lines (4,959 characters) across 12 sections, last generated in May 2026. It introduces the site as "Allogene Therapeutics". It tells AI engines the business works in Biotechnology, Cell Therapy and Gene Therapy. It describes 4 products, including ALLO-501, ALLO-715 and ALLO-316. Services it lists include Clinical Trial Support, Manufacturing Services, Regulatory Consulting and Research Collaboration. The audience it names is Cancer patients and caregivers, aged Adults 18+ (United States, Europe). Technologies it mentions include HTTPS and Clinical Data Management Systems. The keywords it claims start with "cell therapy", "biotechnology", "clinical trials" and "regenerative medicine". It gives the company type as Public.

# Allogene Therapeutics

## About
Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic chimeric antigen receptor (CAR) T cell therapies for cancer. The company leverages a proprietary manufacturing platform that enables the production of off-the-shelf cell therapies from healthy donors, eliminating the need for patient-specific cell collection. This approach aims to provide faster, more accessible treatments compared to traditional autologous therapies. Allogene's pipeline targets both hematologic malignancies and solid tumors, with several candidates currently in clinical trials. The company collaborates with leading academic institutions and research centers to advance its scientific platform. Allogene's therapies are designed to be readily available, reducing treatment delays and logistical challenges for patients and healthcare providers. The company maintains a strong emphasis on safety, scalability, and cost-effectiveness in its development programs. Allogene's leadership team brings decades of experience in cell therapy, oncology, and biopharmaceutical development. The company has established manufacturing capabilities to support late-stage clinical trials and potential commercial launch. Allogene actively engages with patient advocacy groups to ensure its therapies address real-world patient needs. The company publishes regula

Google lists allogene.com for about 276 keywords, which together bring an estimated 3,201 organic visits a month.

The latest technical audit of allogene.com scored 0 out of 100 overall. The audit makes 12 recommendations in all, and 4 of the 4 listed first are rated high priority or critical.

Allogene Therapeutics's company profile names bluebirdbio.com, crispergenetics.com, sparktherapeutics.com and novartis.com as competitors. Its own llms.txt adds regeneron.com and genentech.com. Outside its market, the domains ranked closest to it in our worldwide ranking are zorritaz.com, agneau.org, malay.news and holavpn.net.

bluebirdbio.com

crispergenetics.com

sparktherapeutics.com

novartis.com

regeneron.com

genentech.com